Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Raymond Fung"'
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0301603 (2024)
BackgroundTransgender people encounter significant barriers when seeking timely, high-quality healthcare, resulting in unmet medical needs with increased rates of diabetes, asthma, chronic obstructive pulmonary disease, and HIV. The paucity of postgr
Externí odkaz:
https://doaj.org/article/d0a84f306b93488da903b9d90866b692
Autor:
Raymond Fung, MD, BSc, FRCPC, Mary Kathleen Greenaway, MD, BSc, MPH, CCFP, FCFP, Giancarlo McEvenue, MD, FRCSC
Publikováno v:
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 350-352 (2021)
Objective: To describe the case of a 17-year-old transgender boy who experienced breast development while on testosterone, having been suppressed with a gonadotropin-releasing hormone (GnRH) agonist prior to testosterone therapy Case report: A 17-yea
Externí odkaz:
https://doaj.org/article/f5b630a1248c4d39864a2990adadb3a5
Publikováno v:
Canadian Medical Education Journal, Vol 11, Iss 4 (2020)
Background: The transgender (trans) population is one of the most underserved in health care. Not only do they face discrimination and stigma from society as a whole, they also have difficulty accessing transition-related care, leading to adverse out
Externí odkaz:
https://doaj.org/article/5113a11f95d24406976a27188fce0162
Autor:
Shireen Samargandy, John Wadie, Haytham Msallak, Albino Chiodo, William El Masri, Bradley Hubbard, Danny Enepekides, Kevin Higgins, Angela Assal, Rebecca Fine, Raymond Fung, Everton Nicholas, Valrie Beadle, Antoine Eskander
Publikováno v:
Head & Neck. 45:595-603
Underreported variation in parathyroid hormone (PTH) assays exists. Using quality improvement methods, we aimed to develop an institution-specific PTH-based protocol to predict hypocalcemia after thyroidectomy.We retrospectively reviewed patients who
Autor:
Emily Krupka, Sarah Curtis, Thomas Ferguson, Reid Whitlock, Nicole Askin, Adam C. Millar, Marshall Dahl, Raymond Fung, Sofia B. Ahmed, Navdeep Tangri, Michael Walsh, David Collister
Publikováno v:
Clinical Journal of the American Society of Nephrology. 17:1305-1315
Gender-affirming hormone therapy modifies body composition and lean muscle mass in transgender persons. We sought to characterize the change in serum creatinine, other kidney function biomarkers, and GFR in transgender persons initiating masculinizin
Autor:
Ashley Lacombe‐Duncan, Mostafa Shokoohi, Yasmeen Persad, Angela Underhill, Nima Machouf, Pierre Côté, Megan Wheatley, Meenakshi Gupta, Luke T. Kyne, Amir A. Besharati, Raymond Fung, L. Y. Louie Chan, Gordon Arbess, Amy Bourns, Quang Nguyen, Mona Loutfy
Publikováno v:
HIV Medicine. 23:324-330
This study aimed to characterize and identify factors associated with HIV care among transgender (trans) women living with HIV (TWLWH) in two urban centres in Canada.Retrospective data were collected from clinic charts of TWLWH aged 16 years and olde
Publikováno v:
Canadian Medical Education Journal, Vol 9, Iss 3 (2018)
Background: The transgender (trans) population faces multiple barriers in accessing health care, with knowledge deficits of health care providers contributing substantially. Trans patients report having to teach health care professionals about their
Externí odkaz:
https://doaj.org/article/9d2e2a3bf72e4c72891906c8ce03362d
Publikováno v:
International Journal of Transgenderism. 18:123-128
Objective: The recommended dose of cyproterone acetate (CPA), an anti-androgen that is commonly used in the hormonal treatment of transgender women, is 50–100 mg daily. Our objective was to determine whether CPA at 25 mg daily would suppress total
Publikováno v:
The Journal of Sexual Medicine. 13:1765-1772
Introduction Spironolactone and cyproterone acetate (CPA) are the two main antiandrogen medications used in feminizing hormone therapy in transgender women. Previous studies have suggested that these two agents might have opposite effects on high-den
Autor:
Raymond Fung, Iliana C. Lega
Publikováno v:
The Journal of Sexual Medicine. 14:173-174